Genedata and AB Enzymes Expand Partnership to Digitalize Strain Development
Genedata Selector positioned as data management platform to increase the efficiency of the discovery process for innovative enzymes
July 2, 2019
Genedata, a leading provider of advanced software solutions for life science R&D, today announced that it has expanded its partnership with AB Enzymes, a member of Associated British Foods and one of the world’s leading enzyme manufacturers. As part of the expanded partnership, AB Enzymes has licensed Genedata Selector® as its central bioinformatics platform for managing the genomic and phenotypic information of all production-relevant organisms. In addition to the software license, Genedata also provides Data Science as well as Managed IT services. This full-service solution provides the required scalability as well as the flexibility for AB Enzymes to address the rapidly evolving needs of digitalization including workflow support, data integration, and process harmonization.
“Our partnership with Genedata allows us to increase the efficiency of our strain development processes,” said Dr. Jari Vehmaanperä, Global R&D Director at AB Enzymes. “With Genedata Selector we can integrate a wide range of complex R&D relevant data and make the data easily accessible within our globally distributed R&D organization.”
Besides functioning as an integrated, highly scalable and secure data management system, Genedata Selector harmonizes complex analysis processes for NGS data across an organization and thus enables the creation of a reproducible strain assessment process. Furthermore, Genedata Selector provides automated, configurable workflows from sample registration to data analysis to reporting; for example, for toxicity screening and strain safety assessment. Finally, the platform provides secure data access for all AB Enzymes scientists globally and serves as an entry point for collaboration and innovation.
Genedata Selector, initially deployed and supported by Genedata in the cloud, is now running within AB Enzymes IT environment supported by Genedata Managed IT Services.
“We are very excited about our collaboration with AB Enzymes, a leader in industrial biotechnology,” said Dr. Othmar Pfannes, CEO of Genedata. “Genedata is committed to working with leaders like AB Enzymes in their quest to digitalize highly complex workflows in order to reduce R&D costs while enabling them in their various innovation processes.”
About AB Enzymes
AB Enzymes is an industrial biotech company specializing in enzymes and their applications. Since 1907, AB Enzymes has been developing, manufacturing and supplying enzymes for baking, beverages, grains and vegetable oil seeds processing, animal feed and technical applications such as pulp and paper, textiles and laundry detergents. The company is part of Associated British Foods and is represented worldwide with offices located in Darmstadt, Rajamäki, Fort Lauderdale, Sao Paulo, Singapore and Shanghai.
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.